News Release

Two Medical University of South Carolina researchers recognized with Translational Science awards

Dr. Carol Feghali-Bostwick and Dr. ReJoyce Green received prestigious awards at this year's Translational Science conference in Washington, D.C.

Grant and Award Announcement

Medical University of South Carolina

Dr. Feghali-Bostwick and Dr. ReJoyce Green

image: Medical University of South Carolina researchers Dr. Carol Feghali-Bostwick (left) and Dr. ReJoyce Green (right) received prestigious Translational Science awards from the Association for Clinical and Translational Science at this year's conference. view more 

Credit: photo by Dorothy Christoforou of the Association for Clinical and Translational Science, used with permission.

Medical University of South Carolina researchers Carol Feghali-Bostwick, Ph.D., and ReJoyce Green, Ph.D., were each recognized with a prestigious Translational Science Award at the Translational Science  conference in Washington, D.C., on April 18. The Association for Clinical and Translational Science (ACTS), a nonprofit membership association of translational scientists from the nation’s leading academic medical centers, hosts the conference and presents the annual awards to recognize investigators for their outstanding contributions to clinical research and translational science.

"The ACTS awards recognize talented investigators who translate their findings ultimately from the bench to the community. Awardees are in all phases of studies and disciplines throughout the workforce, which includes investigators, trainees, educators and research teams as well as the advancement of diversity, inclusion and health equity,” said ACTS president Linda B. Cottler, Ph.D.

Feghali-Bostwick received the award for Contributing to the Diversity and Inclusiveness of the Translational Workforce. The award recognizes individuals who, through their careers of mentoring, policymaking or team building have contributed to a more inclusive and diverse workforce.

“Dr. Feghali-Bostwick is an incredible mentor and advocate for individuals in clinical and translational science,” said South Carolina Clinical & Translational Research (SCTR) Institute co-director Kathleen Brady, M.D., Ph.D. “She has worked tirelessly and with enthusiasm to increase diversity and inclusion in the clinical and translational workforce. I cannot think of anyone more deserving of this award.”

Feghali-Bostwick is an internationally recognized translational researcher and leader in the field of scleroderma and systemic sclerosis and the SmartState and Kitty Trask Holt Endowed Chair for Scleroderma Research. She is also passionate about ensuring that the next generation of translational researchers are well-trained and reflect the diversity of the community. She has mentored more than 30 young researchers, many of them physician-scientists, and was awarded the prestigious Peggy Schachte Research Mentor Award in 2018. She directs both SCTR’s Translational Workforce Development program, which offers cutting-edge training to clinical and translational research professionals, and SCTR’s TL1 program, a mentored research training program for predoctoral students with strong interests in pursuing careers in clinical and/or translational research. She also previously co-directed SCTR’s KL2 mentoring program, which aims to transition early-stage investigators to an independent research career. She leads the Advancement, Recruitment, and Retention of Women (ARROW) program at MUSC. Since the creation of ARROW, the number of women faculty in the College of Medicine has increased substantially as has the number of women faculty earning senior faculty appointments and tenure. She also directs STEM-Coaching and Resources for Entrepreneurial Women (CREW), which offers mentorship, coaching and training opportunities to increase the number of women, especially underserved minority women, who not only become entrepreneurs but remain engaged in entrepreneurial activities throughout their careers.

“I am deeply honored to receive the award,” said Feghali-Bostwick. “I am especially grateful for the MUSC Translational Workforce Development and ARROW teams who continue to work tirelessly to promote equity.”

Green received the 2023 ACTS Outstanding Trainee: Post-Doctoral Award. The award recognizes high productivity and impact of postdoctoral work with potential for changing care or health policy.

“Dr. Green is an outstanding clinician-scientist, who has developed a unique mix of clinical and methodological skills and has a vision for applying them to impact public health,” said SCTR associate director and substance use investigator Kevin Gray, M.D., who nominated Green for the award. “This prestigious award is a testament to the national impact of Dr. Green’s work as a translational scientist and postdoctoral scholar at MUSC.” Gray, along with Lindsay Squeglia, Ph.D., co-directs MUSC’s Youth Collaborative, which offers clinical services, research opportunities and education programs focused on preventing and addressing youth substance use.

Green, who completed her graduate work in clinical psychology at the University of California, Los Angeles, is the author of more than 30 peer-reviewed publications. She first came to MUSC to complete the clinical internship requirement of her doctoral degree and has since joined the Squeglia Laboratory as a postdoctoral fellow. She opted to come to MUSC because she wanted to take a more lifespan approach to substance use disorder, studying not only adults but also children and adolescents. She has become a vital team member of the Youth Collaborative, providing important insights by applying her robust statistical models to large datasets. Green believes that such rigorous statistical analysis can point the way forward for clinical care of substance use disorder.  

“If we're able to better identify some of the top factors that contribute to a child initiating substance use, then those might be factors we can target with an intervention or maybe our prevention efforts could address a particular factor that we're seeing the most often,” said Green.


About MUSC

Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $298 million in research funds in fiscal year 2022, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding, with more than $220 million. For information on academic programs, visit

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned and equity stake),with approximately 2,700 beds and four additional hospital locations in development; more than 350 telehealth sites and connectivity to patients’ homes; and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit

MUSC has a total enterprise annual operating budget of $5.1 billion. The nearly 26,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research, and patient care.

About the SCTR Institute

The South Carolina Clinical & Translational Research (SCTR) Institute is the catalyst for changing the culture of biomedical research, facilitating the sharing of resources and expertise and streamlining research-related processes to bring about large-scale change in clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice. To learn more, visit

About ACTS

The Association for Clinical and Translational Science (ACTS) uniquely provides an outstanding platform for enhancing education, research, and public policy related to clinical and translational science. ACTS members consist of leaders, investigators, and trainees from academic medical centers, government, industry, and philanthropy. ACTS focuses on four realms: research, education, advocacy, and mentoring. Additional information is available at the ACTS website at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.